

FW

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:

Paul A. Krieg

Serial No.: 10/799,417

Filed: March 12, 2004

For: Methods for Modulating Angiogenesis
with Apelin Compositions

Art Unit: 1638

Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO-1449, "List of Information Disclosed by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right Applicants may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Kathryn H. Wade

Kathryn H. Wade
Reg. No. 54,682

SUTHERLAND ASBILL & BRENNAN LLP
999 Peachtree Street, NE
Atlanta, Georgia 30309-3996
(404) 853-8000
Our Docket: 20825-0004

I hereby certify that this correspondence is being deposited with the United States Postal Service by First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 6, 2005.

Kathryn H. Wade

Kathryn H. Wade - Reg. No. 54,682

FORM PTO-1449, adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 20825-0064	SERIAL NO. 10/799,417	FILING DATE March 12, 2004
APPLICANT Paul A. Krieg		GROUP 1638

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2004/0033495	Feb. 19, 2004	Murray et al.	435	6	Aug. 1, 2002
	AB	2003/0092618	May 15, 2003	Hinuma et al.	514	12	Jun. 27, 2002
	AC	6,492,324	Dec. 10, 2002	Hinuma et al.	514	2	Feb. 22, 1999
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
						YES	NO
	AF	WO00/68224	11/16/2000	PCT	Smithkline Beecham Corporation	X	
	AG						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	CAYABYAB et al., 2000, "Apelin, the Natural Ligand of the Orphan Seven-Transmembrane Receptor APJ, Inhibits Human Immunodeficiency Virus Type 1 Entry," <i>Journal of Virology</i> , 7(24):11972-11976.
	AI	DEVIC et al., 1999, "Amino acid sequence and embryonic expression of <i>msr/apj</i> , the mouse homolog of Xenopus X-msr and human APJ," <i>Mechanisms of Development</i> , 84:199-203.
	AJ	DEVIC et al., 1999, "Expression of Endothelial Precursors of a New Family of Receptors Sharing Similarities with CXC Chemokine Receptors," <i>Pathologie Biologie</i> 47(4):330-338.
	AK	Eyeteck Study Group, 2003, "Anti-Vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration," <i>Ophthalmology</i> , 2003, 110(5):979-86.
	AL	HOSOYA et al., 2000, "Molecular and Functional Characteristics of APJ," <i>The Journal of Biological Chemistry</i> , 275(28):21061-21067.
	AM	KATUGAMPOLA et al., 2001, "[¹²⁵ I]-(Pyr ¹)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man," <i>British Journal of Pharmacology</i> , 132:1255-1260.
	AN	SAINT-GENIEZ et al., 2002, "Expression of the murine <i>msr/apj</i> receptor and its ligand apelin is upregulated during formation of the retinal vessels," <i>Mechanisms of Development</i> , 110:183-186.
	AO	
	AP	
	AQ	
	AR	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.